What Hong Kong’s First-Ever Five-Year Plan Means for Biopharma
Hong Kong recently announced its first-ever Five-Year Plan, a sign of closer alignment with mainland China. With a clearer roadmap to 2030, what are the implications for biopharma? A…
Patrick is the managing editor of PharmaBoardroom
Hong Kong recently announced its first-ever Five-Year Plan, a sign of closer alignment with mainland China. With a clearer roadmap to 2030, what are the implications for biopharma? A…
With a huge investment from AstraZeneca at its core, can the Spanish city of Barcelona really now rival more established European life sciences ecosystems? Back in 2023, Barcelona was…
Korea, the world’s 13th-largest pharma market, is rolling out its biggest reform to pharma pricing in a generation, slashing what it pays for generics and using the savings to get…
Japan is resetting itself as a clinical trial destination. Costs have halved, local data requirements are being relaxed, and the country is actively courting the global biotechs that have long…
Korea’s position as a clinical trials hub did not happen overnight. The country has treated clinical development as a matter of deliberate government policy for the better part of two…
The global AI-in-clinical-trials market is forecast to grow at a 22.6 percent CAGR through 2030, reaching roughly USD 6.5 billion, as sponsors push CROs to demonstrate concrete efficiency gains rather…
Taiwan’s population of just 23 million people and contested political status should, in theory, harm its chances of becoming a globally relevant clinical trials hub. In fact, these two factors…
China has rapidly become the world’s leading country for clinical trial volume, alongside the stratospheric growth of its local biotech industry, which now accounts for almost a third of the…
Novo Nordisk has rebranded as ‘Novo’ and plans to enter new therapeutic areas as part of CEO Maziar Mike Doustdar’s push to reinvigorate growth. The company has already reinvented itself…
Diabetes is surging in Africa. But, in a continent where healthcare systems are set up to support treatments for infectious – not non-communicable – diseases, can pharma companies step up…
Germany is the default first-choice European market for launching new, innovative medicines. But with the country’s pricing system under growing strain from both national and international pressures, some in the…
The global contract manufacturing market is booming, but fragmented. The well-established names of the CDMO space – Lonza, Thermo Fisher, WuXi AppTec, WuXi Biologics, and Samsung Biologics – account for…
See our Cookie Privacy Policy Here
